Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.
Yehuda Z CohenAllison L ButlerKatrina MillardMaggi Witmer-PackRebeka LevinCecilia Unson-O'BrienRoshni PatelIrina ShimeliovichJulio C C LorenziJill HorowitzStephen R WalshShu LinJoshua A WeinerAnna TseAlicia SatoChelsey BennettBryan MayerKelly E SeatonNicole L YatesLindsey R BadenAllan C deCampMargaret E AckermanMichael S SeamanGeorgia D TomarasMichel C NussenzweigMarina CaskeyPublished in: PloS one (2019)
Single and repeated doses of the combination of 3BNC117 and 10-1074 were well tolerated in healthy adults. These data support the further development of the combination of 3BNC117 and 10-1074 as a long-acting injectable form of pre-exposure prophylaxis for the prevention of HIV-1 infection.